Letter by Turc et al regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: Analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials"

Stroke

Volumn 46, Issue 2, 2014, Pages e43-e44

  Turc, Guillaume ^a   Tisserand, Marie ^a   Seners, Pierre ^a   Oppenheim, Catherine ^a   Baron, Jean Claude ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTERY OCCLUSION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; FIBRINOLYTIC THERAPY; HUMAN; LETTER; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANKIN SCALE; RECURRENT DISEASE; SEIZURE; CEREBRAL HEMORRHAGE; PROCEDURES; STANDARDS; STROKE;

CEREBRAL HEMORRHAGE; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84940379891     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007747     Document Type: Letter

References (3)

1. Rao NM, Levine SR, Gornbein JA, Saver JL. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke. 2014;45:2728-2733. doi: 10.1161/STROKEAHA.114.005135.
2. Seners P, Turc G, Tisserand M, Legrand L, Labeyrie MA, Calvet D, et al. Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors. Stroke. 2014;45:2004-2009. doi: 10.1161/STROKEAHA.114.005426.
3. Tisserand M, Seners P, Turc G, Legrand L, Labeyrie MA, Charron S, et al. Mechanism of unexplained neurological deterioration following intravenous thrombolysis. Stroke. 2014;45:3527-3534. doi: 10.1161/STROKEAHA.114.006745.